Placeholder

The Nose Knows

$30.00

Copyright: This PDF purchase is for a Single user for review or filing purposes only. The PDF is watermarked. If you are interested in a PDF reprint to post on your website or distribute electronically, or hard-copy reprints, please contact Marah Walsh at mwalsh@pharmavoice.com.

SKU: 1828. Category: .

Product Description

Many of the properties that make the nose an effective way for an illicit drug user to get a “fix” are actually qualities that doctors and patients are seeking for legitimate treatments — a non-injection form that delivers medication in highly targeted, quickly absorbed doses. Britannia Pharmaceuticals Ltd., a U.K.-based niche pharmaceutical company is breaking new ground with a novel drug-delivery platform — a nasal powder formulation — to meet such a need. The first compound the company has selected using this unique delivery platform is apomorphine for treating the symptoms associated with Parkinson’s disease.
Apomorphine was a natural selection for the privately held company, whose areas of expertise lie principally in the development of products for Parkinson’s disease and opiate detoxification. Apomorphine has been used for years in injectable form to provide a quick reversal for Parkinson’s patients experiencing the immobility associated…

Sidebar:
A Virtual Model

Experts on this topic
Alex Duckworth. Director, Britannia Pharmaceuticals Ltd., Surrey, United Kingdom; Britannia is a privately held, virtual niche pharmaceutical company specialising in products for ­diseases with orphan indications, which are normally not ­developed by larger pharmaceutical companies
Pete Lambert. Technical manager, Britannia Pharmaceuticals Ltd., Surrey, United Kingdom; Britannia is a privately held, virtual niche pharmaceutical company specialising in products for ­diseases with orphan indications, which are normally not ­developed by larger pharmaceutical companies

FEEDBACK